Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 22 results.
User Information
Export Records
  1. 1.   Tumor-targeting Salmonella typhimurium A1-R is a highly effective general therapeutic for undifferentiated soft tissue sarcoma patient-derived orthotopic xenograft nude-mouse models
  2. Igarashi, Kentaro; Kawaguchi, Kei; Kiyuna, Tasuku; Miyake, Kentaro; Miyake, Masuyo; Singh, Arun S; Eckardt, Mark A; Nelson, Scott D; Russell, Tara A; Dry, Sarah M; Li, Yunfeng; Yamamoto, Norio; Hayashi, Katsuhiro; Kimura, Hiroaki; Miwa, Shinji; Tsuchiya, Hiroyuki; Singh, Shree Ram; Eilber, Fritz C; Hoffman, Robert M
  3. Biochemical and Biophysical Research Communications. 2018, Mar 18; 497(4): 1055-1061.
  1. 2.   Inhibition of multi-drug resistant HIV-1 reverse transcriptase by nucleoside beta-triphosphates
  2. Dash, C.; Ahmadibeni, Y.; Hanley, M. J.; Pandhare, J.; Gotte, M.; Le Grice, S. F. J.; Parang, K.
  3. Bioorganic & Medicinal Chemistry Letters. 2011, Jun; 21(12): 3519-3522.
  1. 3.   Antibody-based inhibitors of HIV infection
  2. Choudhry, V.; Zhang, M. Y.; Dimitrova, D.; Prabakaran, P.; Dimitrov, A. S.; Fouts, T. R.; Dimitrov, D. S.
  3. Expert Opinion on Biological Therapy. 2006, MAY; 6(5): 523-531.
  1. 4.   Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: A new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains
  2. Himmel, D. M.; Das, K.; Clark, A. D.; Hughes, S. H.; Benjahad, A.; Oumouch, S.; Guillemont, J.; Coupa, S.; Poncelet, A.; Csoka, I.; Meyer, C.; Andries, K.; Nguyen, C. H.; Grierson, D. S.; Arnold, E.
  3. Journal of Medicinal Chemistry. 2005, DEC 1; 48(24): 7582-7591.
  1. 5.   Sensitive phenotypic detection of minor drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants
  2. Nissley, D. V.; Halvas, E. K.; Hoppman, N. L.; Garfinkel, D. J.; Mellors, J. W.; Strathern, J. N.
  3. Journal of Clinical Microbiology. 2005, NOV; 43(11): 5696-5704.
  1. 6.   Crystallography and the design of anti-AIDS drugs: Conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors
  2. Das, K.; Lewi, P. J.; Hughes, S. H.; Arnold, E.
  3. Progress in Biophysics and Molecular Biology. 2005, JUN; 88(2): 209-231.
  1. 7.   Evolution of human immunodeficiency virus under selection and weak recombination
  2. Rouzine, I. M.; Coffin, J. M.
  3. Genetics. 2005, MAY; 170(1): 7-18.
  1. 8.   Panel of prototypical infectious molecular HIV-1 clones containing multiple nucleoside reverse transcriptase inhibitor resistance mutations
  2. Johnston, E.; Dupnik, K. M.; Gonzales, M. J.; Winters, M. A.; Rhee, S. Y.; Imamichi, T.; Shafer, R. W.
  3. Aids. 2005, APR 29; 19(7): 731-733.
  1. 9.   Fixed conformation nucleoside analogs effectively inhibit excision-proficient HIV-1 reverse transcriptases
  2. Boyer, P. L.; Julias, J. G.; Marquez, V. E.; Hughes, S. H.
  3. Journal of Molecular Biology. 2005, JAN 21; 345(3): 441-450.
  1. 10.   Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases
  2. Sarafianos, S. G.; Das, K.; Hughes, S. H.; Arnold, E.
  3. Current Opinion in Structural Biology. 2004, DEC; 14(6): 716-730.
  1. 11.   A novel antimicrobial indolizinium alkaloid from Aniba panurensis
  2. Klausmeyer, P.; Chmurny, G. N.; McCloud, T. G.; Tucker, K. D.; Shoemaker, R. H.
  3. Journal of Natural Products. 2004, OCT; 67(10): 1732-1735.
  1. 12.   Caffeoyl-based affinity acetylators of HIV-1 integrase as novel pharmacological
  2. Patil, S. S.; Shkriabai, N.; Zhang, X. C.; Pais, G. C. G.; Svarovskaia, E. S.; Merch, C.; Pathak, V. K.; Pommier, Y.; Le Grice, S.; Kvaratskhelia, M.; Burke, T. R.
  3. Abstracts of Papers of the American Chemical Society. 2004, AUG 22; 228(Part 1): 329-MEDI, Abstract U967-329-MEDI, Abstract U967.
  1. 13.   HIV-1 populations are large, highly diverse, and characterized by frequent recombination in drug-naive and drug-resistant individuals
  2. Maldarelli, F.; Kearney, M.; Palmer, S.; Polis, M.; Mican, J.; Stephens, R.; Rock, D.; Mellors, J.; Coffin, J.
  3. Antiviral Therapy. 2004, AUG; 9(4): U51-U51.
  1. 14.   Detection and characterization of rare drug resistant HIV-1 RT variants using a sensitive phenotypic assay
  2. Nissley, D. V.; Julias, J.; Mellors, J.; Hughes, S.; Strathern, J.
  3. Antiviral Therapy. 2004, AUG; 9(4): U98-U99.
  1. 15.   Action of Anti-HIV drugs and resistance: Reverse transcriptase inhibitors and protease inhibitors
  2. Imamichi, T.
  3. Current Pharmaceutical Design. 2004 10(32): 4039-4053.
  1. 16.   Getting back on track, or what to do when apoptosis is de-railed - Recoupling oncogenes to the apoptotic machinery
  2. Fearnhead, H. O.
  3. Cancer Biology & Therapy. 2004 3(1): 21-28.
  1. 17.   Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants
  2. Das, K.; Clark, A. D.; Lewi, P. J.; Heeres, J.; de Jonge, M. R.; Koymans, L. M. H.; Vinkers, H. M.; Daeyaert, F.; Ludovici, D. W.; Kukla, M. J.; De Corte, B.; Kavash, R. W.; Ho, C. Y.; Ye, H.; Lichtenstein, M. A.; Andries, K.; Pauwels, R.; de Bethune, M. P.; Boyer, P. L.; Clark, P.; Hughes, S. H.; Janssen, P. A. J.; Arnold, E.
  3. Journal of Medicinal Chemistry. 2004 47(10): 2550-2560.
  1. 18.   A potent anti-HIV immunotoxin blocks spreading infection by primary HIV type 1 isolates in multiple cell types
  2. Lueders, K. K.; De Rosa, S. C.; Valentin, A.; Pavlakis, G. N.; Roederer, M.; Hamer, D. H.
  3. Aids Research and Human Retroviruses. 2004 20(2): 145-150.
  1. 19.   Updated, blinded, multicentre comparison of the sensitivity of different technologies to detect and quantify a minor drug-resistant HIV-1 variant
  2. Halvas, E.; Aldrovandi, G.; Balfe, J. P.; Beck, I.; Boltz, V.; Frenkel, L.; Hazelwood, J.; Johnson, V.; Kearney, M.; Kovacs, A.; Kuritzkes, D.; Metzner, K.; Nissley, D.; Nowicki, M.; Ziermann, R.; Zhao, Y.; Jennings, C.; Bremer, J.; Brambilla, D.; Mellors, J.
  3. Antiviral Therapy. 2003, JUN; 8(3): U91, Abstract 92-U92, Abstract 92.
  1. 20.   Detection of rare drug-resistant HIV-1 reverse transcriptase variants using a sensitive phenotypic assay
  2. Nissley, D. V.; Halvas, E.; Garfinkel, D.; Mellors, J.; Strathern, J.
  3. Antiviral Therapy. 2003, JUN; 8(3): U92, Abstract 93-U93, Abstract 93.
  1. 21.   Analogues of caffeic acid phenylethyl ester (CAPE) as affinity covalent modifiers of HIV-1 integrase
  2. Patil, S. S.; Zhang, X. C.; Pais, G. C. G.; Kvaratskhelia, M.; Svarovskaia, E. S.; Merch, C.; Pathak, V. K.; Pommier, Y.; Le Grice, S.; Burke, T. R.
  3. Abstracts of Papers of the American Chemical Society. 2003 226(Part 2): U22-U22.
  1. 22.   Drug resistance mutations can affect dimer stability of HIV-1 protease at neutral pH
  2. Xie, D.; Gulnik, S.; Gustchina, E.; Yu, B.; Shao, W.; Qoronfleh, W.; Nathan, A.; Erickson, J. W.
  3. Protein Science. 1999 8(8): 1702-1707.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel